2014
DOI: 10.1590/0004-2730000003308
|View full text |Cite
|
Sign up to set email alerts
|

Long-term risks of bisphosphonate therapy

Abstract: The objective this study was to summarize long-term risks associated with bisphosphonate therapy. Search of relevant medical publications for data from clinical trials, trial extensions, observational studies and post-marketing reports. Trial extensions and modifications did not reveal significant long-term safety issues. Observational data suggest at least as many benefits as risks. Post-marketing reports of musculoskeletal pain, osteonecrosis of the jaw and atypical femur fractures have been widely circulate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0
13

Year Published

2014
2014
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 23 publications
(30 citation statements)
references
References 52 publications
(41 reference statements)
0
17
0
13
Order By: Relevance
“…It has been reported that knocking down mdt‐15 causes decreased expression of SCDs, including fat‐6 and fat‐7 , suggesting that fat‐6 and fat‐7 were mdt‐15 targets . Glu‐SeMet (0.01 µ m ) downregulated the mRNA levels of fat‐6 and fat‐7 in wild‐type N2 C. elegans under high‐glucose diet (Figure ) which might be due to the decreased expression of mdt‐15 .…”
Section: Resultsmentioning
confidence: 91%
See 2 more Smart Citations
“…It has been reported that knocking down mdt‐15 causes decreased expression of SCDs, including fat‐6 and fat‐7 , suggesting that fat‐6 and fat‐7 were mdt‐15 targets . Glu‐SeMet (0.01 µ m ) downregulated the mRNA levels of fat‐6 and fat‐7 in wild‐type N2 C. elegans under high‐glucose diet (Figure ) which might be due to the decreased expression of mdt‐15 .…”
Section: Resultsmentioning
confidence: 91%
“…[27] It has been reported that knocking down mdt-15 causes decreased expression of SCDs, including fat-6 and fat-7, suggesting that fat-6 and fat-7 were mdt-15 targets. [44] Glu-SeMet (0.01 µm) downregulated the mRNA levels of fat-6 and fat-7 in wild-type N2 C. elegans under high-glucose diet (Figure 4) which might be due to the decreased expression of mdt-15. Our results showed that Glu-SeMet (0.01 µm) did not affect the mRNA level of nhr-49 under high-glucose diet, suggesting that nhr-49 might not be responsible for the downregulation of fat-6 and fat-7 by Glu-SeMet.…”
Section: Effects Of Glu-semet On the Mrna Levels Of Several Lipid Metmentioning
confidence: 98%
See 1 more Smart Citation
“…[31] points that potential benefits of using bisphosphonates still exceed the risk of potential complications, especially rare ones like AFF. In addition, he suggests that it is possible to have a break after 3-5 years ("drug holiday") in using BPs.…”
Section: Resultsmentioning
confidence: 99%
“…Seit den 1990-er Jahren sind Bisphosphonate zunehmend in klinischer Verwendung als antiresorptive Substanzen bei metabolischen Knochenerkrankungen. Bei folgenden Indikationen werden Bisphosphonate derzeit eingesetzt: bei Osteoporose Alendronat oral, Risedronat oral, Ibandronat oral und i. v. und Zoledronat i. v., bei ossär metastasierten Karzinomen und Myelom Zoledronat, Ibandronat und Pamidronat i. v., bei Morbus Paget Alendronat oral, Risedronat oral und Zoledronat i. v., sowie bei akuter Hyperkalzämie Zoledronat, Ibandronat und Pamidronat i. v. Das Ziel dieser Übersicht ist, aufbauend auf vorhandenen Studien, positive sowie negative Aspekte einer Langzeittherapie mit Bisphosphonaten zusammenzufassen [1,2,3,4,5].…”
Section: Introductionunclassified